loading page

Efficacy of lorlatinib treatment in ALK-rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
  • Tomoyo Taketa,
  • Takahito Nakamura
Tomoyo Taketa
Hoshigaoka Iryo Center
Author Profile
Takahito Nakamura
Hoshigaoka Iryo Center
Author Profile

Abstract

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) designed to penetrate the blood brain barrier. We report 2 cases of patients with ALK-rearrangement non-small cell carcinoma associated with severe symptomatic CNS metastases and poor performance status. Treatment with lorlatinib improved their neurological condition and performance status.

Peer review status:ACCEPTED

06 Dec 2020Submitted to Clinical Case Reports
08 Dec 2020Assigned to Editor
08 Dec 2020Submission Checks Completed
29 Dec 2020Reviewer(s) Assigned
24 Jan 2021Review(s) Completed, Editorial Evaluation Pending
29 Jan 2021Editorial Decision: Accept